Literature DB >> 20336161

Pituitary gland: can prolactinomas be cured medically?

Mark E Molitch.   

Abstract

A systematic review and meta-analysis by Dekkers et al. has assessed the effects of dopamine agonist withdrawal in patients with hyperprolactinemia. But not all dopamine agonists are the same, and much depends on the criteria for patient selection and the drug withdrawal strategy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20336161     DOI： 10.1038/nrendo.2009.278

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

Review 1.  Dopamine as a prolactin (PRL) inhibitor.

Authors:  N Ben-Jonathan; R Hnasko
Journal:  Endocr Rev       Date:  2001-12       Impact factor: 19.871

2.  Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.

Authors:  George Kontogeorgos; Eva Horvath; Kalman Kovacs; Claire Coire; Ricardo V Lloyd; Bernd W Scheithauer; Harley S Smyth
Journal:  Acta Neuropathol       Date:  2005-11-23       Impact factor: 17.088

Review 3.  Advances in the treatment of prolactinomas.

Authors:  Mary P Gillam; Mark E Molitch; Gaetano Lombardi; Annamaria Colao
Journal:  Endocr Rev       Date:  2006-05-26       Impact factor: 19.871

4.  Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.

Authors:  Annamaria Colao; Antonella Di Sarno; Ermelinda Guerra; Rosario Pivonello; Paolo Cappabianca; Ferdinando Caranci; Andrea Elefante; Luigi M Cavallo; Francesco Briganti; Sossio Cirillo; Gaetano Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2007-06-15       Impact factor: 3.478

Review 5.  Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.

Authors:  Olaf M Dekkers; Joep Lagro; Pia Burman; Jens Otto Jørgensen; Johannes A Romijn; Alberto M Pereira
Journal:  J Clin Endocrinol Metab       Date:  2009-10-30       Impact factor: 5.958

6.  Perivascular fibrosis in prolactinomas: is it increased by bromocriptine?

Authors:  A M Landolt; V Osterwalder
Journal:  J Clin Endocrinol Metab       Date:  1984-06       Impact factor: 5.958

7.  Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland.

Authors:  M M Esiri; J S Bevan; C W Burke; C B Adams
Journal:  J Clin Endocrinol Metab       Date:  1986-08       Impact factor: 5.958

8.  Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.

Authors:  J Kharlip; R Salvatori; G Yenokyan; G S Wand
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

9.  Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.

Authors:  Annamaria Colao; Antonella Di Sarno; Paolo Cappabianca; Carolina Di Somma; Rosario Pivonello; Gaetano Lombardi
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

10.  Effect of Dopamine Agonists on Lactotroph Adenomas of the Human Pituitary.

Authors:  Lucia Stefaneanu; Kalman Kovacs; Bernd W. Scheithauer; George Kontogeorgos; Darren L. Riehle; Thomas J. Sebo; David Murray; Sergio Vidal; Ami Tran; Michael Buchfelder; Rudolf Fahlbusch
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056
  10 in total
  3 in total

Review 1.  Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.

Authors:  Miao Yun Xia; Xiao Hui Lou; Shao Jian Lin; Zhe Bao Wu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

2.  High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas.

Authors:  Gherardo Mazziotti; Tatiana Mancini; Marilda Mormando; Ernesto De Menis; Antonio Bianchi; Mauro Doga; Teresa Porcelli; Pier Paolo Vescovi; Laura De Marinis; Andrea Giustina
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

3.  Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration.

Authors:  Charlotte Sonigo; Justine Bouilly; Nadège Carré; Virginie Tolle; Alain Caraty; Javier Tello; Fabian-Jesus Simony-Conesa; Robert Millar; Jacques Young; Nadine Binart
Journal:  J Clin Invest       Date:  2012-09-24       Impact factor: 14.808
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.